Clinical Trials Logo

Histiocytosis clinical trials

View clinical trials related to Histiocytosis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02012231 Terminated - Colorectal Cancer Clinical Trials

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Start date: February 2014
Phase: Phase 1
Study type: Interventional

The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered PLX8394 in patients with advanced solid tumors. An additional objective is to identify a Recommended Phase 2 (RP2D) for further evaluation in the Extension Cohorts (Phase IIa portion). The study objective of the Extension Cohorts (PART 2 portion) is to assess the objective tumor response and the PK, PD, and safety of PLX8394 when the RP2D is used in patients with advanced BRAF-mutated cancers.

NCT ID: NCT01050439 Terminated - Lymphoma Clinical Trials

Unrelated Donor Transplant for Malignant and Non-Malignant Disorders

Start date: November 2002
Phase: Phase 2
Study type: Interventional

Unrelated matched donor (cord blood, bone marrow or peripheral blood) allogeneic stem cell transplantation (UDAlloSCT) with either myeloablative or reduced intensity conditioning will be well tolerated and result in a high degree of engraftment in patients with selected malignant and non malignant disorders.

NCT ID: NCT00618540 Terminated - Clinical trials for Histiocytosis, Langerhans-cell

Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

Start date: January 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Giving a monoclonal antibody, such as alemtuzumab, and chemotherapy drugs, such as fludarabine and melphalan, before a donor stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells and helps stop the growth of abnormal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving alemtuzumab together with fludarabine and melphalan followed by a donor stem cell transplant works in treating young patients with resistant Langerhans cell histiocytosis.

NCT ID: NCT00176826 Terminated - Clinical trials for Hematologic Diseases

T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders

Start date: September 2000
Phase: Phase 2/Phase 3
Study type: Interventional

The hypothesis is to determine if a preparative regimen of busulfan, cyclophosphamide, and antithymocyte globulin (ATG) plus allogeneic stem cell transplantation will be effective in the treatment of immune deficiencies and histiocytic disorders.

NCT ID: NCT00008216 Terminated - Lymphoma Clinical Trials

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Start date: July 1996
Phase: Phase 2
Study type: Observational [Patient Registry]

RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.

NCT ID: NCT00002947 Terminated - Lung Cancer Clinical Trials

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Start date: October 1996
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of indium In 111 pentetreotide in treating patients who have refractory cancer.